Characterization of the patient cohort (n = 3082)
. | No. of patients . | Percentage of patients . |
---|---|---|
History of AML | ||
De novo AML | 2546 | 82.6 |
Secondary AML (s-AML) | 334 | 10.8 |
t-AML | 202 | 2.0 |
Total | 3082 | 100.0 |
Cytogenetic subgroup | ||
Normal | 1472 | 47.8 |
t(15;17)* | 130 | 4.2 |
t(8;21) | 88 | 2.9 |
Trisomy 8 | 129 | 4.2 |
11q23/MLL | 109 | 3.5 |
5q-/-5 | 31 | 1.0 |
7q-/-7 | 60 | 1.9 |
inv(16)/t(16;16)† | 119 | 3.9 |
inv(3)/t(3;3) | 44 | 1.4 |
t(6;9)(p23;q34) | 6 | 0.2 |
Complex aberrant | 430 | 14.0 |
Other aberrations | 400 | 15.0 |
Total | 3018 | 100.0 |
FAB subtype | ||
M0 | 132 | 4.8 |
M1 | 491 | 17.8 |
M2 | 1054 | 38.2 |
M3 | 85 | 3.1 |
M3v | 51 | 1.8 |
M4 | 484 | 17.5 |
M4eo | 118 | 4.3 |
M5a | 107 | 3.9 |
M5b | 114 | 4.1 |
M6 | 112 | 4.1 |
M7 | 14 | 0.5 |
Total | 2762 | 100.0 |
. | No. of patients . | Percentage of patients . |
---|---|---|
History of AML | ||
De novo AML | 2546 | 82.6 |
Secondary AML (s-AML) | 334 | 10.8 |
t-AML | 202 | 2.0 |
Total | 3082 | 100.0 |
Cytogenetic subgroup | ||
Normal | 1472 | 47.8 |
t(15;17)* | 130 | 4.2 |
t(8;21) | 88 | 2.9 |
Trisomy 8 | 129 | 4.2 |
11q23/MLL | 109 | 3.5 |
5q-/-5 | 31 | 1.0 |
7q-/-7 | 60 | 1.9 |
inv(16)/t(16;16)† | 119 | 3.9 |
inv(3)/t(3;3) | 44 | 1.4 |
t(6;9)(p23;q34) | 6 | 0.2 |
Complex aberrant | 430 | 14.0 |
Other aberrations | 400 | 15.0 |
Total | 3018 | 100.0 |
FAB subtype | ||
M0 | 132 | 4.8 |
M1 | 491 | 17.8 |
M2 | 1054 | 38.2 |
M3 | 85 | 3.1 |
M3v | 51 | 1.8 |
M4 | 484 | 17.5 |
M4eo | 118 | 4.3 |
M5a | 107 | 3.9 |
M5b | 114 | 4.1 |
M6 | 112 | 4.1 |
M7 | 14 | 0.5 |
Total | 2762 | 100.0 |
A total of 136 cases of FAB M3/M3v morphology were associated with 130 cases of t(15;17) in chromosome banding analyses because of additional 6 cryptic PML-RARA rearrangements.
A total of 118 cases of FAB M4eo morphology were associated with 119 cases of inv(16)/t(16;16) because of atypical morphology in one case.